Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma (Q38028411)

27 August 2017

Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma (English)

1 reference

27 August 2017

María José Méndez-Vidal

1

1 reference

27 August 2017

Esther Martínez Ortega

2

1 reference

27 August 2017

Alvaro Montesa Pino

3

1 reference

27 August 2017

Begoña Pérez Valderrama

4

1 reference

27 August 2017

Ruth Viciana

5

1 reference

27 August 2017

1 September 2012

1 reference

Cancer and Metastasis Reviews

27 August 2017

1 reference

27 August 2017

31 Suppl 1

1 reference

27 August 2017

S19-27

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-012-9355-y

27 August 2017

0 references

cites work

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Reversible posterior leucoencephalopathy syndrome associated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Megestrol acetate in cachexia and anorexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Pharmacologic management of the older patient with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

A new reality: achieving cholesterol-lowering goals in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Targeting mTOR in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

10.1007/S10555-012-9355-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference